Recent advances include Imugene’s off-the-shelf CD19 CAR T therapy demonstrating a 75% response rate in diffuse large B-cell lymphoma patients during a phase Ib trial, showcasing promise for allogeneic immunotherapies. Concurrently, pioneering work on antibody-payload conjugates explores dual-payload ADCs to overcome tumor resistance mechanisms by delivering two cytotoxic agents simultaneously. Additionally, innovative strategies for combating methicillin-resistant Staphylococcus aureus (MRSA) involve antibody–polysialic acid conjugates inducing bacterial calcification and immune activation. These insights underscore a multi-faceted approach in oncology and antimicrobial research combining cellular therapies, biochemical conjugates, and immunomodulation to improve clinical outcomes.